Oncotarget

Reviews:

Lipidome in colorectal cancer

Guifang Yan, Liqi Li, Bo Zhu and Yongsheng Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:33429-33439. https://doi.org/10.18632/oncotarget.7960

Metrics: PDF 3912 views  |   HTML 3981 views  |   ?  


Abstract

Guifang Yan1,*, Liqi Li2,*, Bo Zhu1 and Yongsheng Li1,3

1 Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China

2 Department of General Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China

3 Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

* These authors contributed equally to this work

Correspondence to:

Bo Zhu, email:

Yongsheng Li, email:

Keywords: lipidome, metabolism, colorectal cancer, fatty acid, cholesterol

Received: December 07, 2015 Accepted: February 25, 2016 Published: March 07, 2016

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths. Understanding its pathophysiology is essential for developing efficient strategies to treat this disease. Lipidome, the sum of total lipids, related enzymes, receptors and signaling pathways, plays crucial roles in multiple cellular processes, such as metabolism, energy storage, proliferation and apoptosis. Dysregulation of lipid metabolism and function contributes to the development of CRC, and can be used towards the evaluation of prognosis. The strategies targeting lipidome have been applied in clinical trails and showed promising results. Here we discuss recent advances in abnormal lipid metabolism in CRC, the mechanisms by which the lipidome regulates tumorigenesis and tumor progression, and suggest potential therapeutic targets for clinical trials.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7960